Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not seen ...

Amgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer drug to its pipeline. The big pharma swooped in after the California biotech reported ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Learn more about whether Kymera Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's ...

Nurix Therapeutics, Inc. is a San Francisco based ... from its proprietary DNA-encoded libraries (“DELS”) of over five billion unique structures that either inhibit or harness E3 ligases ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on wallstreetbets Subreddit Page by MADD-Scientis. In this ...

Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

Analysts' ratings for VYNE Therapeutics VYNE over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table provides a quick overview of their recent ratings ...

During the last three months, 5 analysts shared their evaluations of Zevra Therapeutics (NASDAQ:ZVRA), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ...

I don't know about you, but Prime Video is the platform I'll be taking advantage of the most this month, simply because of how many attention-snatching movies are coming in March 2025. What I'm ...

During the five years of share price growth, Protagonist Therapeutics moved from a loss to profitability. That kind of transition can be an inflection point that justifies a strong share price ...